Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · Canada

Clinical Trials in London, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6553 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:20 UTC
6553
Studies in scope
all four open statuses
3487
Recruiting now
open to new participants
880
Lead sponsors
across recruiting studies
Top sites
Toronto 2818 Montreal 1913 Vancouver 1187 Calgary 1068 Edmonton 1018
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's110 Western University, Canada37 AstraZeneca36 Novartis Pharmaceuticals26 Eli Lilly and Company22 Canadian Cancer Trials Group19 AbbVie18 National Cancer Institute (NCI)17 Hoffmann-La Roche17 Janssen Research & Development, LLC15 Children's Oncology Group14 Sanofi14 Pfizer13 University Health Network, Toronto13 Sunnybrook Health Sciences Centre10 Takeda10 Ottawa Hospital Research Institute10 Population Health Research Institute9 Merck Sharp & Dohme LLC9 Novo Nordisk A/S9 McMaster University9 Incyte Corporation9 University of British Columbia7 Alexion Pharmaceuticals, Inc.7 Ottawa Heart Institute Research Corporation7 Show all 283
Site location
Toronto2818 Montreal1913 Vancouver1187 Calgary1068 Edmonton1018 Ottawa884 London878 Hamilton811 Québec682 Halifax535 Winnipeg454 Sherbrooke264 Kingston254 Kelowna176 Brampton143 Surrey138 Victoria129 St. John's126 Barrie125 Saskatoon125 Chicoutimi100 Moncton92 Mississauga89 Greater Sudbury83 Regina82 Show all 248
All 248 locations
Target enrolment
to

Trials with a site in London

878 of 6553 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Calgary, Winnipeg, London, Chicoutimi, Montr Al, Rimouski
2027-11-23
Not yet open
Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility
NCT07654517Idiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)
DrugPirfenidone
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1
44
London, Toronto
2027-04-01
Not yet open
WSO BEAT STROKE Initiative
NCT06606054Stroke, PFO - Patent Foramen Ovale, Atrial Fibrillation (AF)
Luciano A. Sposato
Not applicable
2,400
London
2027-03
Recruiting
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 3
30
Edmonton, Vancouver, London, Toronto, Montreal
2027-01-21
Not yet open
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
NCT07858331Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD
DrugsWegovy·Semaglutide
Kristin Clemens
Phase 4
880
London
2027-01-01
Not yet open
University of British Columbia
Observational
102
Calgary, Cranbrook, Kelowna, New Westminster, Surrey, Vancouver, Winnipeg, London
2027-01
Not yet open
LifeWave, Inc.
Not applicable
100
London
2027-01
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
25
London
2026-12-30
Not yet open
Hana Serajeddini
Not applicable
50
London
2026-12-02
Not yet open
Virtual Reality to Advance Dementia Care and Quality of Life
NCT07893678Dementia, Agitation, Behavioural and Psychological Symptoms of Dementia, Major Neurocognitive Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
10
London
2026-12-01
Not yet open
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
NCT07281027New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
DrugsAnakinra·Tocilizumab
Yale University
Phase 3
438
London, Toronto
2026-12-01
Not yet open
Canadian Myeloma Research Group
Phase 1
108
Edmonton, Halifax, London, Ottawa, Toronto, Montreal
2026-12
Not yet open
AbbVie
Phase 3
520
Victoria, London, Montreal
2026-11-30
Not yet open
Novo Nordisk A/S
Phase 3
1,408
Vancouver, Victoria, Moncton, Halifax, Hamilton, London, Trois-Rivières, Québec
2026-11-11
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
120
London
2026-11-01
Not yet open
Feasibility of Transcutaneous Spinal Stimulation in Rehabilitation
NCT07898150Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injuries (SCI), Spinal Cord Injuries and Disorders (SCI/D)
Janelle Unger
Not applicable
15
London
2026-11-01
By invitation
BioMIND Biospecimen Repository
NCT07912736Alzheimer's Disease (AD), Cognitive Impairment
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
1,000
London
2026-11
Not yet open
Nutrisol, LLC
Not applicable
200
London
2026-11
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2/3
150
London
2026-11
Not yet open
Dr. Grace Parraga
Observational
35
London
2026-11
Not yet open
Mitosynergy LLC
Not applicable
88
London
2026-11
Recruiting
Nordic Naturals
Not applicable
600
London
2026-10-26
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Edmonton, Red Deer, Vancouver, Moncton, Truro, London, Mississauga, North York
2026-10-26
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2026-10-01
Not yet open
The BASIC-S Feasibility Study for Vascular Risk Reduction
NCT07755631Hypertension (HTN), Vascular Diseases, Stroke, Dementia
Andrew Appleton
Not applicable
120
London
2026-10-01
Not yet open
Western University, Canada
Not applicable
200
London
2026-10-01
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2026-10-01
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
30
London
2026-10
Recruiting
Holland Bloorview Kids Rehabilitation Hospital
Phase 2
100
Hamilton, Kingston, London, Toronto
2026-10
Not yet open
A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
NCT07711288Postprandial Glycemic Control, Prediabetic Overweight and Obese Adults
Lembas
Not applicable
35
London
2026-10
Not yet open
McMaster University
Phase 4
124
Calgary, Hamilton, London, Québec, Sherbrooke
2026-09-30
Not yet open
Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)
NCT07785388HIV, Vascular Disease, Inflammation, Pain Management
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
60
London
2026-09-30
Recruiting
Novartis Pharmaceuticals
Phase 2
259
London, Toronto
2026-09-29
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Edmonton, London, Montreal, Ottawa, Regina
2026-09-29
Recruiting
Novartis Pharmaceuticals
Phase 3
382
London, Québec
2026-09-21
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3
1
London
2026-09-17
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
1
London
2026-09-17
Recruiting
Takeda
Phase 3
324
Calgary, Hamilton, London, Toronto, Lévis, Montreal
2026-09-10
Not yet open
Labral Repair vs Reconstruction
NCT07608237Femoral Acetabular Impingement
Western University, Canada
Not applicable
220
London
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Calgary, Edmonton, Winnipeg, Halifax, Brampton, Greater Sudbury, London, Mississauga
2026-09-01
Not yet open
Trauma Therapy for Weight-Based Bullying in Children
NCT07685990Pediatric Obesity, Weight-based Bullying, Psychological Trauma
Western University
Not applicable
30
London
2026-09-01
Not yet open
Aeovian Pharmaceuticals, Inc.
Phase 2
42
London
2026-09-01
Not yet open
University of Pennsylvania
Not applicable
17
London
2026-09-01
Not yet open
Spencer B Chambers
Not applicable
100
London
2026-09-01
Not yet open
Western University, Canada
Phase 4
164
London
2026-09-01
Not yet open
Post-osteoporotic Fracture Exercise Program
NCT07595991Osteoporosis, Osteoporotic Fracture
Western University, Canada
Not applicable
100
London
2026-09
Recruiting
Accelerated iTBS for PTSD and Depression
NCT07682207Post Traumatic Stress Disorder PTSD, Major Depressive Disorder (MDD)
Lawson Research Institute of St. Joseph's
Not applicable
16
London
2026-09
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
160
London
2026-09
Not yet open
MICRO-ultrasound Guided Prostate SBRT
NCT07737457Prostate Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
112
London
2026-09
Not yet open
Everwell Health
Not applicable
80
London
2026-09
Recruiting
Canada Royal Enoch Phytomedicine Co., Ltd.
Not applicable
72
London
2026-08-30
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Calgary, Edmonton, Greater Sudbury, London, Scarborough Village, Montreal
2026-08-28
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Barrie, Etobicoke, Greater Sudbury, Hamilton, Kingston, London, Markham, Newmarket
2026-08-24
Recruiting
Oruka Therapeutics, Inc.
Phase 2
200
Surrey, Barrie, London, Peterborough, Waterloo
2026-08-21
Recruiting
AstraZeneca
Phase 3
7,000
Calgary, Edmonton, Vancouver, Winnipeg, Saint John, London, Scarborough Village, Toronto
2026-08-21
Recruiting
Arrae
Not applicable
100
London
2026-08-19
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Calgary, Vancouver, Kingston, London, Toronto, Montreal
2026-08-05
Recruiting
Arrae
Not applicable
120
London
2026-08-05
Recruiting
DDAVP Effect by TEG6 in Cardiac Surgery
NCT07179991Intraoperative Bleeding
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2026-08-01
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
NCT07893821Atrial Fibrillation (Paroxysmal), Hypertension, Heart Failure With Preserved Ejection Fraction (HFPEF)
Pavel Antiperovitch
Not applicable
10
London
2026-08-01
Not yet open
Reus Research
Not applicable
80
London
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Winnipeg, London, North York, Toronto, Vaughan
2026-07-31
Recruiting
Novartis Pharmaceuticals
Phase 2
100
London, Markham
2026-07-30
Recruiting
Eisai Limited
Observational
400
Calgary, Edmonton, Vancouver, Victoria, Kingston, London, Mississauga, Ottawa
2026-07-30
Recruiting
Boehringer Ingelheim
Phase 3
448
Calgary, Edmonton, London, Toronto
2026-07-27
Recruiting
Rousselot BVBA
Not applicable
120
London
2026-07-22
Recruiting
AstraZeneca
Phase 3
915
Calgary, Abbotsford British Columbia, Barrie, Hamilton, Kingston, London, Mississauga, Montreal
2026-07-16
Recruiting
Rousselot BVBA
Not applicable
120
London
2026-07-15
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Edmonton, London, Montreal, Québec
2026-07-10
Not yet open
¹²⁹Xe(XENON) MRI Program
NCT07533981Healthy Volunteers - Male and Female
Alexei Ouriadov
Not applicable
200
London
2026-07-01
Not yet open
Assessment of a Wearable Ultrafiltration Device
NCT06832696Hemodialysis, Ultrafiltration
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
18
London
2026-07-01
Not yet open
GenCanna Acquisition Corp
Not applicable
150
London
2026-07
Not yet open
Nexira
Not applicable
105
London
2026-07
Active, closed
Boehringer Ingelheim
Phase 2
344
Surrey, Victoria, Guelph, Hamilton, London, Stouffville, Toronto, Chicoutimi
2026-06-30
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
42
London
2026-06-17
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
40
London
2026-06-15
Active, closed
AstraZeneca
Phase 2
326
Calgary, Vancouver, Halifax, London, Toronto, Montreal
2026-06-11
Recruiting
Joelle Helou
Not applicable
58
London
2026-06-10
Not yet open
Staph Nasal Decolonization to Improve Function and Feeding
NCT07524894Radiation Mucositis, Staphylococcal Aureus Infection, Head and Neck Cancer
DrugMupirocin
David Palma
Phase 2
126
London
2026-06-01
Recruiting
Bayer
Phase 3
117
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2026-06-01
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Edmonton, Vancouver, Kentville, Barrie, Hamilton, London, Toronto, Montreal
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Edmonton, Vancouver, Halifax, Kentville, London, Mississauga, Toronto, Vaughan
2026-05-22
Recruiting
ParagonClinicals Inc.
Phase 2
82
Brampton, London, Mississauga, North York
2026-05-20
Not yet open
¹⁹F (Perfluoropropane) MRI
NCT07305532Healthy Volunteers - Male and Female
Alexei Ouriadov
Not applicable
200
London
2026-05-20
Recruiting
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
London
2026-05-14
Recruiting
Ipsen
Phase 3
350
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Brampton, London, North Bay
2026-05-14
Recruiting
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Bridgewater, Brampton, Etobicoke, London, Sarnia, Toronto, Chicoutimi, Mirabel
2026-05-11
Recruiting
Eli Lilly and Company
Phase 2
60
Greenfield Park, Lethbridge, London, Vaughan
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Greenfield Park, Lethbridge, London, Vaughan
2026-05-04
Recruiting
Pfizer
Phase 3
2,400
London, Sarnia, Montreal, Pierrefonds-Roxboro, Québec
2026-05-04
Active, closed
Chobani
Not applicable
32
London
2026-05-01
Recruiting
Hoffmann-La Roche
Phase 3
360
London
2026-04-27
Recruiting
Western University, Canada
Phase 4
60
London
2026-04-24
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
London, Ottawa, Montreal
2026-04-23
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Edmonton, Vancouver, Hamilton, London, Oshawa, Toronto, Montreal
2026-04-21
Recruiting
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
NCT07411716PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS), Cholestasis, Intrahepatic
Children's Hospital of Eastern Ontario
Observational
220
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2026-04-21
Recruiting
Alimentiv Inc.
Phase 4
60
Vancouver, Hamilton, London, Scarborough Village
2026-04-20
Not yet open
Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
NCT03166072Low Vision, One Eye, Unspecified Eye, Low Vision Blindness
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
150
London
2026-04-20
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
650
Fredericton, Hamilton, London, Québec, Verdun
2026-04-16
Recruiting
Sensory Motor Arousal Regulation Treatment (SMART) Study
NCT06035809PTSD, Post-traumatic Stress Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
80
London
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Chicoutimi, London, Ottawa, Richmond Hill, Toronto, Verdun
2026-04-14
Recruiting
Boehringer Ingelheim
Phase 3
670
London, Sault Ste. Marie
2026-04-13
Recruiting
Pfizer
Phase 3
1,712
London, Stouffville, Sherbrooke
2026-04-08
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Greater Sudbury, Halifax, London
2026-03-26
Recruiting
Boehringer Ingelheim
Phase 2
132
Calgary, London
2026-03-23
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Edmonton, Guelph, London, Toronto
2026-03-19
Active, closed
Oruka Therapeutics, Inc.
Phase 2
160
Edmonton, Surrey, Barrie, London, North Bay, Peterborough, Toronto, Waterloo
2026-03-19
Recruiting
London Health Sciences Centre Research Institute
Observational
2,145
London
2026-03-18
Recruiting
University of Sydney
Phase 3
540
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, London, Toronto, Montreal
2026-03-13
Recruiting
Novartis Pharmaceuticals
Phase 2
272
London, Ottawa
2026-03-09
Recruiting
Dr. Grace Parraga
Observational
40
London
2026-03-02
Recruiting
Papillex Inc.
Not applicable
60
London
2026-03-01
Not yet open
Vora Life LLC
Not applicable
30
London
2026-03
Not yet open
Susan Scollie
Not applicable
20
Halifax, London
2026-03
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Calgary, Surrey, Moncton, Halifax, London
2026-02-24
Recruiting
Oruka Therapeutics, Inc.
Phase 2
240
Edmonton, Surrey, Fredericton, Ajax, London, Markham, Peterborough, Toronto
2026-02-23
Recruiting
Rousselot BVBA
Not applicable
60
London
2026-02-18
Recruiting
Boehringer Ingelheim
Phase 3
286
Vancouver, London, Toronto, Montreal
2026-02-16
Recruiting
Restrictive Fluid Management In Liver Transplantation (REFIL)
NCT07695363Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Centre hospitalier de l'Université de Montréal (CHUM)
Not applicable
866
Vancouver, London, Montreal
2026-02-15
Not yet open
Daniel Breadner
Phase 1
10
London
2026-02-15
Recruiting
Eli Lilly and Company
Phase 3
300
Calgary, Chicoutimi, Edmonton, London, Ottawa, Québec, Vancouver
2026-02-05
Recruiting
QuickSilver Scientific
Not applicable
90
London
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Calgary, Vancouver, Halifax, Hamilton, London, Toronto, Montreal
2026-02-04
Not yet open
Western University, Canada
Observational
10
London
2026-02-01
Recruiting
Piloting a Brief, Online Intervention for Suicidality in Sexual and Gender Minority Youth
NCT07402265Suicidal Thoughts, Sexual and Gender Minorities, Youth
Western University
Not applicable
250
London
2026-02-01
Not yet open
Jewish General Hospital
Phase 1/2
125
London, Ottawa, Montreal
2026-02
Not yet open
Western University, Canada
Observational
30
London
2026-01-31
Recruiting
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT07245394Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
DrugsTremfya·Guselkumab
TIDHI Innovation Inc.
Observational
200
Calgary, Fredericton, Hamilton, Barrie, Brampton, London, Mississauga, Oakville
2026-01-29
Recruiting
Bruyère Health Research Institute.
Phase 3
120
Brampton, Kingston, London, Newmarket, Ottawa, Montreal
2026-01-28
Active, closed
Eli Lilly and Company
Phase 3
600
Brampton, Courtice, Hamilton, Joliette, London, Québec, Sherbrooke, Toronto
2026-01-24
Recruiting
University of Southern California
Not applicable
600
Vancouver, London, Ottawa
2026-01-23
Recruiting
Sanofi
Phase 3
751
Edmonton, Hamilton, London, New Westminster, Toronto
2026-01-22
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Calgary, Ajax, Barrie, London, Mississauga, Niagara Falls, Richmond Hill, Windsor
2026-01-20
Recruiting
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
NCT07188246Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
DrugsKeytruda·Pembrolizumab
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
40
London
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Calgary, Edmonton, Halifax, London, Toronto, Montreal, Québec, Sherbrooke
2026-01-19
Recruiting
Vorasidenib Maintenance for IDH Mutant Astrocytoma
NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma
DrugVorasidenib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
468
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Kingston, London
2026-01-16
Recruiting
Sanofi
Phase 3
751
Toronto, Edmonton, Hamilton, London, New Westminster
2026-01-16
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
20
London
2026-01-15
Recruiting
St. Justine's Hospital
Phase 1/2
50
Calgary, Edmonton, Vancouver, Winnipeg, London, Ottawa, Toronto, Montreal
2026-01-12
Recruiting
Javelin Medical
Not applicable
2,000
Hamilton, London
2026-01-09
Active, closed
Hoffmann-La Roche
Phase 2
120
London, Markham, Mississauga, Newmarket
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Calgary, Edmonton, London, Toronto, Windsor, Chicoutimi, Greenfield Park, Montreal
2026-01-06
Recruiting
Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment
NCT06948149Creatine, Exercise, Mild Cognitive Impairment (MCI)
Western University, Canada
Not applicable
140
London
2026-01-01
Recruiting
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
NCT07272902Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Rate Control
Nova Scotia Health Authority
Not applicable
84
Halifax, Hamilton, London, Montreal
2026-01-01
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2026-01-01
Not yet open
University of British Columbia
Not applicable
914
Edmonton, Barrie, London, North York, Vancouver
2026-01-01
Not yet open
Western University
Not applicable
32
London
2026-01
Not yet open
Bragg Live Food Products
Not applicable
24
London
2026-01
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Edmonton, Brampton, London, Toronto
2025-12-22
Recruiting
London Health Sciences Centre Research Institute
Phase 2
60
London
2025-12-16
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
NCT07282015Hidradenitis Suppurativa
Novartis Pharmaceuticals
Observational
142
Calgary, Winnipeg, Fredericton, St. John's, Cobourg, Hamilton, London, Markham
2025-12-12
Recruiting
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
NCT06858748Asthma, Chronic Obstructive Pulmonary Disease (COPD), Chronic Cough (CC)
McMaster University
Observational
240
Vancouver, Hamilton, London, Ottawa, Montreal, Québec, Sherbrooke
2025-12-11
Active, closed
Zealand Pharma
Phase 3
28
London
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Edmonton, Vancouver, Victoria, Halifax, Hamilton, London, Montreal, Québec
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Calgary, Edmonton, London, Toronto, Montreal
2025-12-09
Recruiting
Aker BioMarine Human Ingredients AS
Not applicable
138
London
2025-12-06
Recruiting
Bristol-Myers Squibb
Phase 3
366
Edmonton, Winnipeg, St. John's, London, Richmond Hill, Toronto, Montreal
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Hamilton, London, Toronto, Whitby
2025-12-02
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
24
London
2025-12-01
Recruiting
Michelle Baczynski
Not applicable
780
Calgary, Edmonton, Vancouver, Hamilton, London, Toronto, Montral, Montreal
2025-12-01
Recruiting
Syndax Pharmaceuticals
Phase 3
468
London, Montreal, Toronto
2025-11-25
Recruiting
Bayer
Phase 3
111
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2025-11-19
Recruiting
UCB Biopharma SRL
Phase 3
320
Barrie, Calgary, Fredericton, London, Québec, Red Deer, Surrey
2025-11-14
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Kelowna, Halifax, London, Ottawa, Peterborough, Toronto, Montreal
2025-11-12
Recruiting
Oral Carnitine in Heart Failure Patients
NCT07201714Heart Failure, Carnitine Deficiency
DrugLevocarnitine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Early Phase 1
20
London
2025-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Moncton, London, North York, Thunder Bay, Mirabel, Québec
2025-11-11
Recruiting
Eli Lilly and Company
Phase 2
252
Hamilton, London, Mississauga, Trois-Rivières
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Edmonton, Vancouver, London, Ottawa, Toronto
2025-11-10
Recruiting
Hamilton Health Sciences Corporation
Phase 3
30
Hamilton, London
2025-11-07
Active, closed
Novo Nordisk A/S
Phase 3
330
Kelowna, Moncton, Halifax, Brampton, Hamilton, London, Pointe-Claire, Victoriaville
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
Moncton, Halifax, Hamilton, London, Oshawa, Toronto, Mirabel
2025-11-05
Active, closed
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
NCT07177157Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
Terry Ponich
Phase 1
150
London
2025-11-05
Recruiting
Sanzyme Biologics Private Limited
Not applicable
100
London
2025-11-05
Not yet open
Western University, Canada
Not applicable
378
London
2025-11-01
Not yet open
Imaging and Treatment Planning for Cardiac Radioablation
NCT06938074Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia (V-Tach), Ischemia, Myocardial
Stewart Gaede
Not applicable
15
London
2025-11-01
Active, closed
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
Citryll BV
Phase 2
108
Barrie, Calgary, London, Newmarket, Winnipeg
2025-10-31
Recruiting
Graminex LLC
Phase 2
120
London
2025-10-29
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
London, Toronto, Boisbriand
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Calgary, Vancouver, Halifax, Hamilton, London, Newmarket, Toronto, Montreal
2025-10-28
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
New Westminster, Hamilton, London, Montreal
2025-10-24
Recruiting
Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
NCT07337161Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma
David Palma
Not applicable
90
London
2025-10-21
Recruiting
Canadian Cancer Trials Group
Phase 2
140
Calgary, Kelowna, Vancouver, Hamilton, Kingston, Kitchener, London, Mississauga
2025-10-21
Recruiting
B2AD-Risk AFDAS Evolution of Burden of AF
NCT06589700Stroke, Atrial Fibrillation
Luciano A. Sposato
Not applicable
24
London
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto
2025-10-15
By invitation
Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors
NCT07100054CDK4/6 Inhibitor, Breast Cancer, CYP3A4 Protein, Human, Drug Interaction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2025-10-10
Recruiting
Bristol-Myers Squibb
Observational
223
Calgary, London, Ottawa, Toronto, Sherbrooke
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Edmonton, Vancouver, Kentville, Barrie, London, Oakville, Toronto, Montreal
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Edmonton, Hamilton, London, Newmarket, Montreal, Québec
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Calgary, Vancouver, Québec, Halifax, Greater Sudbury, Hamilton, London, Mississauga
2025-10-02
Not yet open
Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
NCT07076914Primary Lung Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
58
London
2025-10-02
Recruiting
AllRock Bio, Inc.
Phase 2
40
Calgary, London
2025-10-01
Recruiting
ImmunityBio, Inc.
Phase 3
507
North Vancouver, Saint John, Brampton, Kitchener, London, Newmarket, Windsor
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Edmonton, Vancouver, Kentville, Barrie, London, Mississauga, Oakville, Toronto
2025-10-01
Active, closed
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Vancouver, London, Toronto, Montreal
2025-10-01
Recruiting
Sanofi
Phase 3
980
Oakville, Brampton, Edmonton, Greater Sudbury, Hamilton, London, Montreal, New Westminster
2025-10-01
Recruiting
Genentech, Inc.
Phase 2
224
London, Montreal
2025-09-29
Recruiting
Weight-Bearing CT Periprosthetic Distal Knee Fractures
NCT06525610Periprosthetic Fracture Around Prosthetic Joint Implant Knee
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
21
London
2025-09-24
Recruiting
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
NCT06942039CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood
DrugsCytarabine IT·Carbo·Mesna·Isotretinoin
C17 Council
Early Phase 1
15
Calgary, Vancouver, Winnipeg, Halifax, Hamilton, London, Ottawa, Montreal
2025-09-23
Recruiting
Sanofi
Phase 4
218
Calgary, London
2025-09-22
Active, closed
Exercise Intensity
NCT07119593Dialysis, Cardioprotection
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
15
London
2025-09-22
Recruiting
CSL Behring
Phase 3
200
Kingston, London, Toronto, Montreal
2025-09-15
Recruiting
Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes
NCT06840756Red Blood Cell Transfusions, Sex Differences, Health Services, Critically Ill Intensive Care Unit Patients
Michelle Zeller
Phase 4
11,082
Hamilton, Kingston, London, Oshawa, Ottawa, Toronto
2025-09-11
Recruiting
AbbVie
Observational
700
Calgary, Edmonton, Winnipeg, Ajax, Belleville, Hamilton, London, Markham
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Calgary, Edmonton, Hamilton, London, Montreal, Sherbrooke, Toronto, Vancouver
2025-09-08
Recruiting
Chris Goodman
Not applicable
141
Kelowna, Saint John, London, Waterloo
2025-09-03
Recruiting
AbbVie
Observational
2,795
Calgary, Edmonton, Fredericton, Barrie, London, Markham, Richmond Hill, Pointe-Claire
2025-09-02
Not yet open
Intermittent Fasting for Inflammation and Depression in Spinal Cord Injury
NCT06807528Spinal Cord Injury, Depression - Major Depressive Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2025-09-01
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
44
New Westminster, London
2025-09-01
Not yet open
Study of Sensory Attenuation in Functional Movement Disorders
NCT06872788Functional Movement Disorder
Western University, Canada
Observational
70
London
2025-09
Not yet open
Testing of a New Joint Protection Program
NCT06963164Hand Osteoarthritis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2025-09
Recruiting
Basilea Pharmaceutica
Phase 3
234
Edmonton, Hamilton, London, Ottawa, Toronto, Vancouver
2025-08-26
Recruiting
Gut Microbiome in Orthopaedics: Revision Total Knee Arthroplasty
NCT06951477Revision Total Knee Arthroplasty, Osteoarthritis, Knee
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
30
London
2025-08-21
Recruiting
MapLight Therapeutics
Phase 2
300
Brampton, London, Toronto, Lévis
2025-08-15
Recruiting
DIALysis With EXpanded Solute Removal
NCT06660277Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), Chronic Kidney Disease Requiring Chronic Dialysis, Pragmatic Randomized Controlled Trial
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
4,800
London, Orillia, Ottawa
2025-08-12
Active, closed
Novo Nordisk A/S
Phase 3
877
Calgary, Vancouver, Winnipeg, Halifax, Brampton, Etobicoke, Hamilton, London
2025-08-11
Recruiting
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
NCT05749094Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy, Optic Neuropathy, Ischemic
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Observational
285
London, Ottawa, Toronto, Montreal, Sherbrooke
2025-08-09
Active, closed
Novartis Pharmaceuticals
Phase 2
96
London, North York, Ottawa, Toronto
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Calgary, Abbotsford British Columbia, Vancouver, Barrie, Brampton, London, Toronto, Chicoutimi
2025-08-06
Active, closed
GlaxoSmithKline
Phase 2
168
Edmonton, Vancouver, London, Toronto
2025-08-06
Recruiting
Eli Lilly and Company
Phase 1
36
Calgary, Edmonton, London, Montreal, Toronto
2025-08-05
Recruiting
Sue Peters
Not applicable
25
London
2025-08-01
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
10
London
2025-08-01
Recruiting
AbbVie
Phase 3
120
Calgary, Edmonton, London
2025-07-28
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
London, Ottawa, Toronto
2025-07-21
Active, closed
Oruka Therapeutics, Inc.
Phase 2
80
Edmonton, Surrey, Hamilton, London, Markham, Peterborough, Toronto, Waterloo
2025-07-18
Recruiting
Western University, Canada
Phase 2
30
London
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Winnipeg, Moncton, London, Toronto, Chicoutimi, Montreal
2025-07-16
Recruiting
Feasibility Trial for a Right Ventricular Failure Platform Trial
NCT06570473Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
DrugsRanolazine·Dapagliflozin
University of Alberta
Phase 2
30
Calgary, Edmonton, Vancouver, London, Ottawa
2025-07-15
Recruiting
Takeda
Phase 3
347
Calgary, London, Toronto
2025-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
426
Hamilton, London, Toronto, Whitby, Montreal
2025-07-10
Recruiting
Ablative Radioembolization of Renal Cell Carcinoma Trial
NCT06642220Renal Cell Carcinoma (RCC), Radioembolization
Derek W. Cool
Phase 2
16
London
2025-07-09
Recruiting
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
NCT07022925Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
IdentifyHer Limited
Observational
110
London
2025-07-04
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Calgary, London, Toronto, Vancouver
2025-07-02
Recruiting
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
NCT05802121Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity
Western University
Early Phase 1
30
London
2025-07-02
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Kelowna, Richmond, Halifax, London, Ottawa, Peterborough, Toronto, Montreal
2025-07-02
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
33
London
2025-07-01
Recruiting
Marea Therapeutics
Phase 2
316
Concord, London, Sarnia, Chicoutimi, Montreal, Québec
2025-06-30
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Calgary, Edmonton, Sherwood Park, Winnipeg, Fredericton, Barrie, Guelph, London
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
290
Edmonton, London, Montreal, Ottawa, Vancouver
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
London, Montreal, Ottawa, Vancouver
2025-06-26
Recruiting
McMaster University
Not applicable
120
Calgary, Vancouver, Halifax, London, Toronto
2025-06-16
Recruiting
The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers
NCT06937814GI Issues, Bowel Movements, Gastrointestinal Symptoms
dsm-firmenich Switzerland AG
Not applicable
250
London
2025-06-16
Active, closed
Incyte Corporation
Phase 3
573
Edmonton, Winnipeg, Fredericton, Hamilton, London, Markham, Mississauga, Saskatoon
2025-06-12
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
London, Montreal, Edmonton, Vancouver
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Vancouver, London, Chicoutimi, Montreal, Québec, Trois-Rivières
2025-06-10
Recruiting
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT06337838Chronic Kidney Diseases, Acute Kidney Injury, Bleeding, Surgery
DrugsDdavp·Desmopressin
Hamilton Health Sciences Corporation
Phase 3
100
London, Montreal
2025-06-09
Recruiting
Celgene
Phase 2
200
Edmonton, London, Ottawa, Toronto, Lévis, Montreal
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Calgary, Vancouver, Winnipeg, Halifax, Hamilton, London, Toronto, Montreal
2025-06-04
Active, closed
Apogee Therapeutics, Inc.
Phase 1
86
London, Peterborough, Richmond Hill, Toronto, Montreal, Québec, Sherbrooke
2025-06-04
Recruiting
McMaster University
Phase 4
242
Hamilton, London
2025-06-02
Recruiting
Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
NCT06877598Prostate Cancer, Sexual Dysfunction, Physiological, Sexual Dysfunction, Psychological, Sexual Dysfunction
University Health Network, Toronto
Observational
575
Vancouver, Winnipeg, Barrie, Edmonton, Kingston, London, Mississauga, Ottawa
2025-06-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Edmonton, London, Toronto, Montreal
2025-05-30
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
London, Toronto, Chicoutimi, Montreal, Greater Sudbury
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Surrey, Winnipeg, St. John's, Barrie, London, Sault Ste. Marie, Toronto, Windsor
2025-05-22
Recruiting
Biogen
Phase 3
180
Vancouver, London
2025-05-22
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Hamilton, London, Ottawa, Montreal, Québec, Sherbrooke
2025-05-15
Recruiting
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
NCT04986605Diffuse Cutaneous Systemic Sclerosis
DrugUvadex
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
15
London
2025-05-14
Recruiting
Hoffmann-La Roche
Phase 3
425
Barrie, Brampton, London, North YORK, Montreal
2025-05-12
Recruiting
Ottawa Hospital Research Institute
Not applicable
50
London, Ottawa
2025-05-08
Recruiting
Caregiver Training to Support Children With Social Communication Challenges
NCT06909279Autism Spectrum Disorder, Suspected Autism, Social Communication Challenges
Western University, Canada
Not applicable
72
London
2025-05-06
Recruiting
Takeda
Phase 3
225
Edmonton, Vancouver, Halifax, London, Toronto
2025-05-06
Recruiting
Alp Sener
Not applicable
120
London
2025-05-03
Recruiting
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NCT06256575Scleroderma, Systemic, Digital Ulcer
Primus Pharmaceuticals
Not applicable
45
Calgary, Halifax, London, Ottawa, Toronto
2025-05-02
Recruiting
Western University, Canada
Not applicable
176
London
2025-05-01
Recruiting
AbbVie
Phase 2
390
Calgary, Edmonton, London, Toronto, Montreal
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
Chicoutimi, London, Toronto, Vancouver
2025-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
London, Ottawa, Montreal
2025-04-22
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
DrugsDactinomycin·Vincrystine·Cytoxan·Paraplatin
Children's Oncology Group
Phase 3
1,656
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, London, Ottawa, Toronto
2025-04-15
Active, closed
Janssen Research & Development, LLC
Phase 3
752
St. John's, Ajax, Barrie, Hamilton, London, Markham, Waterloo, Montreal
2025-04-15
Recruiting
BeOne Medicines
Phase 3
250
Hamilton, London, Ottawa, Greenfield Park, Montreal, SaintJerome
2025-04-10
Recruiting
Novel Approach to Conduction System Pacing With Use of Ultrasound
NCT06815783Conduction Block, Atrioventricular, Bundle-Branch Block
Habib Khan
Not applicable
152
London
2025-04-10
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Victoria, Halifax, London, Sarnia, Toronto, Waterloo, Chicoutimi, Montreal
2025-04-09
Recruiting
Amylyx Pharmaceuticals Inc.
Phase 1
48
Calgary, Hamilton, London, Montreal
2025-04-07
Recruiting
Canadian Cancer Trials Group
Phase 2
128
Abbotsford British Columbia, Surrey, Vancouver, Hamilton, London, Newmarket, Ottawa, Toronto
2025-04-07
Recruiting
Feasibility of a Diet Intervention for Juvenile Arthritis
NCT06474546Arthritis, Juvenile, Arthritis, Childhood, Juvenile Idiopathic Arthritis
The Hospital for Sick Children
Not applicable
54
Winnipeg, Hamilton, London, Ottawa, Toronto, Montreal, Saskatoon
2025-04-07
Recruiting
Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
NCT06156176Long-COVID, Long COVID-19, Post-COVID-19 Syndrome, Post-COVID Syndrome
Lawson Research Institute of St. Joseph's
Not applicable
60
London
2025-04-01
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Calgary, Vancouver, Halifax, Hamilton, Kingston, London, Toronto, Sherbrooke
2025-04-01
Not yet open
Western University, Canada
Early Phase 1
10
London
2025-04-01
Active, closed
Hoffmann-La Roche
Phase 2
162
London, Markham, Mississauga, Québec
2025-04-01
Recruiting
Pfizer
Phase 3
674
Calgary, Red Deer, Winnipeg, Barrie, Guelph, London, Markham, Newmarket
2025-04-01
Not yet open
Western University, Canada
Not applicable
30
London
2025-04
Recruiting
Ontario Clinical Oncology Group (OCOG)
Phase 2
40
Vancouver, Victoria, Hamilton, Kingston, London, Ottawa
2025-03-28
Recruiting
AstraZeneca
Phase 3
600
Calgary, Edmonton, Winnipeg, Halifax, London, Toronto, Montreal, Québec
2025-03-27
Recruiting
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
NCT06174220Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
DrugTideglusib
Hamilton Health Sciences Corporation
Phase 2
120
Calgary, Vancouver, Victoria, St. John's, Halifax, Hamilton, Kingston, London
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Edmonton, London, Montreal, Québec, Sherbrooke
2025-03-20
Active, closed
Amgen
Phase 3
1,105
Surrey, Winnipeg, Halifax, Brampton, Concord, Hamilton, London, Nepean
2025-03-17
Active, closed
Hoffmann-La Roche
Phase 4
274
London, Ottawa, Toronto, Québec
2025-03-14
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Calgary, Edmonton, Vancouver, London, Toronto
2025-03-07
Recruiting
Canadian Cancer Trials Group
Phase 3
230
Calgary, Vancouver, Hamilton, Kingston, London, Newmarket, Toronto, Windsor
2025-03-07
Recruiting
AstraZeneca
Phase 3
5,000
Edmonton, Surrey, Vancouver, Winnipeg, Saint John, Halifax, Etobicoke, London
2025-03-03
Not yet open
Genomic First Testing in Chronic Kidney Disease
NCT06794567Chronic Kidney Disease(CKD), Genetic Kidney Disease
Dervla Connaughton
Observational
2,400
London
2025-03-01
Not yet open
Passive Thoughts in Functional Movement Disorders
NCT06439017Functional Movement Disorder
Western University, Canada
Observational
60
London
2025-03
Recruiting
Incyte Corporation
Phase 3
600
Calgary, Edmonton, Sherwood Park, Vancouver, Winnipeg, Barrie, Cobourg, London
2025-02-28
Recruiting
Summit Therapeutics
Phase 3
780
Edmonton, Etobicoke, London, Montreal
2025-02-27
Recruiting
Novo Nordisk A/S
Phase 3
510
Calgary, Edmonton, Vancouver, London, Scarborough Village, Toronto, Montreal
2025-02-17
Recruiting
AbbVie
Phase 3
420
London, Montreal
2025-02-13
Active, closed
Sanofi
Phase 3
231
London, Montreal, Québec
2025-02-12
Active, closed
GlaxoSmithKline
Phase 2
307
Kelowna, Ajax, London, Toronto, Windsor, Trois-Rivières
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
London, Ottawa, Québec
2025-02-07
Recruiting
Biobeat Digital Home Monitoring Feasibility
NCT06417996Thoracic Surgery, Home Monitoring
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
48
London
2025-02-01
Not yet open
EVAluation of Erythrocytosis PRospEctive Cohort STudy
NCT06785870Erythrocytosis, Polycythemia, Polycythemia Secondary, Polycythemia Vera
Cyrus Hsia
Observational
1,500
London
2025-02-01
Recruiting
Western University, Canada
Not applicable
68
London
2025-02-01
Active, closed
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
50
London
2025-02-01
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
30
London
2025-01-20
Active, closed
CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC)
NCT06393400Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
DrugsFecal Microbiota Transplantation·Nab-paclitaxel·Gemcitabine
John Lenehan
Phase 1
20
London
2025-01-08
Recruiting
David Palma
Phase 2
98
Vancouver, Saint John, London, Montreal
2025-01-07
Not yet open
Surgery and Reducing Ionizing Radiation of the Unknown Primary
NCT06578871Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
90
London
2025-01-01
Recruiting
Adult Bladder and Quality of Life Evaluation in Spina Bifida
NCT07642466Spina Bifida or Spinal Dysraphism
Blayne Welk
Observational
300
London
2025-01-01
Not yet open
Handwriting Analysis in Movement Disorders.
NCT06436287Movement Disorders
Western University, Canada
Observational
100
London
2025-01
Not yet open
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
15
London
2025-01
Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
DrugsDocetaxel·Carboplatin
Canadian Cancer Trials Group
Phase 3
236
Calgary, Edmonton, Vancouver, Brampton, Kitchener, London, Ottawa, Toronto
2024-12-30
Active, closed
Amgen
Phase 2
61
Edmonton, Brampton, London, Toronto, Montreal
2024-12-26
Recruiting
Cytokinetics
Phase 3
1,800
Edmonton, Kelowna, Surrey, Vancouver, Victoria, Winnipeg, Kingston, London
2024-12-19
Recruiting
Sanofi
Phase 2
84
London, Toronto, Montreal, Québec
2024-12-19
Active, closed
argenx
Phase 3
154
Gatineau, London, Vancouver
2024-12-18
Recruiting
Canadian Myeloma Research Group
Phase 2
75
Edmonton, St. John's, Halifax, London, Toronto, Montreal
2024-12-12
Active, closed
GlaxoSmithKline
Phase 1
86
London, Toronto, Montreal
2024-12-11
Recruiting
Belimumab in Autoimmune Hepatitis
NCT06381453Autoimmune Hepatitis
DrugBelimumab
University Health Network, Toronto
Phase 2
48
Calgary, Vancouver, Hamilton, London, Ottawa, Toronto
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Barrie, London, Toronto, Montreal
2024-12-11
Not yet open
Venous Excess Ultrasound for Personalized Resuscitation in Septic Shock
NCT06696391Septic Shock, Sepsis, Shock, Critical Care, Intensive Care
Western University, Canada
Phase 3
80
London
2024-12-01
Recruiting
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
NCT06725121Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
DrugsAtezolizumab & Bevacizumab·Tecentriq·Avastin
University Health Network, Toronto
Phase 1/2
48
London, Toronto
2024-12
Active, closed
AbbVie
Observational
1,314
Calgary, Vancouver, Saint John, Halifax, London, Ottawa, Toronto, Lévis
2024-11-26
Recruiting
University Health Network, Toronto
Phase 2
204
London, Toronto
2024-11-26
Recruiting
International CRDS Registry
NCT06508164Calcium Release Deficiency Syndrome
Population Health Research Institute
Observational
500
Calgary, Edmonton, Vancouver, Hamilton, London, Ottawa, Montreal, Québec
2024-11-21
Active, closed
Daiichi Sankyo
Phase 3
700
London, Montreal, Ottawa, Saskatoon, Toronto
2024-11-19
Active, closed
Pfizer
Phase 3
636
Edmonton, Red Deer, London
2024-11-15
Recruiting
Western University, Canada
Not applicable
60
London
2024-11-12
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Vancouver, London, Toronto
2024-11-11
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
London, Toronto, Montreal
2024-11-04
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2024-11-01
By invitation
Long-term Follow up of the Stability 1 Trial
NCT06885372LET, ACL Reconstruction, Osteoarthritis (OA) of the Knee
Western University, Canada
Not applicable
510
Banff, Calgary, New Westminster, Winnipeg, Hamilton, Kingston, London
2024-11-01
Recruiting
Western University, Canada
Not applicable
105
London
2024-11-01
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Calgary, London, Toronto
2024-10-29
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
DrugsParaplatin·Etoposide·Carboplatin
Children's Oncology Group
Phase 2
240
Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, London, Toronto, Montreal
2024-10-22
Recruiting
Patient Reported Outcomes Targeting Early Chest Tube Removal (PROTECTR) Study
NCT06444854Lung Surgery, Chest Tube Removal, Enhanced Recovery After Surgery (ERAS)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
130
London
2024-10-22
Active, closed
Canadian Radiostereometric Analysis Network
Not applicable
30
Winnipeg, Halifax, London
2024-10-21
Recruiting
McMaster University
Not applicable
68
Hamilton, London, Sherbrooke
2024-10-20
Recruiting
DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery
NCT06519747Atrial Fibrillation, Atrial Flutter
Population Health Research Institute
Observational
750
Hamilton, London, St. Catharines, Sherbrooke
2024-10-15
Active, closed
Ipsen
Observational
424
Montreal, Calgary, London, Ottawa, Vancouver
2024-10-14
Recruiting
Australasian Gastro-Intestinal Trials Group
Phase 2
78
Edmonton, Vancouver, London, Ottawa, Toronto, Regina, Saskatoon
2024-10-14
Active, closed
Eli Lilly and Company
Phase 2
143
London, Montreal
2024-10-10
Active, closed
Incyte Corporation
Phase 3
349
Calgary, Edmonton, Sherwood Park, Barrie, Cobourg, London, Toronto, Québec
2024-10-10
Active, closed
Incyte Corporation
Phase 3
346
Edmonton, Barrie, London, Toronto, Québec, Saskatoon
2024-10-10
Recruiting
Xencor, Inc.
Phase 1/2
270
London, Montreal, Scarborough, Vancouver
2024-10-10
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
20
London
2024-09-27
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Surrey, Vancouver, Barrie, London, Toronto, Montreal, Saint-Charles-Borromée, Saint-Jérôme
2024-09-27
Recruiting
GlaxoSmithKline
Phase 2
393
Calgary, New Westminster, Vancouver, London, Toronto, Montreal, Terrebonne
2024-09-27
Recruiting
Western University, Canada
Phase 4
60
London
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
Edmonton, Vancouver, Winnipeg, London
2024-09-26
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Vancouver, London, Toronto
2024-09-25
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Calgary, Chicoutimi, Greater Sudbury, Guelph, Halifax, Kelowna, Lévis, London
2024-09-24
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
Calgary, Vancouver, London
2024-09-18
Active, closed
argenx
Phase 3
141
Halifax, London, Montreal, Ottawa, Québec, Toronto
2024-09-18
Recruiting
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06081348Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder, Fragile X Syndrome
DrugsZoloft·Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2
130
Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Toronto
2024-09-16
Recruiting
M3-JIA: Making Mindfulness Matter for Children With JIA
NCT06376149Juvenile Idiopathic Arthritis, Children, Mental Health, Mental Well-being
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
74
Hamilton, London, Toronto
2024-09-12
Recruiting
Regeneron Pharmaceuticals
Phase 3
560
Calgary, Edmonton, London, Toronto, Montreal, Québec
2024-09-09
Recruiting
AbbVie
Phase 2
590
Calgary, Edmonton, Greater Sudbury, London, Vaughan, Montreal, Québec
2024-09-04
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Calgary, London, Ottawa, Toronto
2024-09-03
Active, closed
argenx
Phase 2
33
London
2024-08-30
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Edmonton, London, Toronto, Montreal
2024-08-28
Active, closed
Gilead Sciences
Phase 3
640
Calgary, London, Montreal, Québec, Toronto
2024-08-28
Recruiting
Naveen Poonai
Not applicable
250
London
2024-08-24
Recruiting
Sanofi
Phase 3
160
London, Toronto, Montreal, Québec
2024-08-21
Recruiting
Breast 3DUS ABUS System Comparison
NCT06118996Breast Diseases
Western University, Canada
Not applicable
30
London
2024-08-18
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Calgary, Edmonton, Bridgewater, London, Toronto
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
London, Fleurimont, Montreal, Québec
2024-08-05
Recruiting
Ottawa Heart Institute Research Corporation
Not applicable
50
London, Ottawa, Toronto, Montreal, Québec
2024-07-30
Active, closed
Annexon, Inc.
Phase 3
659
Calgary, Edmonton, London, Ottawa
2024-07-30
Active, closed
OncoVerity, Inc.
Phase 2
140
Calgary, Edmonton, Vancouver, London, Ottawa, Toronto, Saskatoon
2024-07-22
Recruiting
Jazz Pharmaceuticals
Phase 3
286
London, Toronto, Montreal
2024-07-19
Active, closed
Celldex Therapeutics
Phase 3
976
Edmonton, Hamilton, London, North Bay, Ottawa, Richmond Hill, Toronto, Windsor
2024-07-19
Recruiting
GlaxoSmithKline
Phase 3
150
Ajax, Hamilton, London
2024-07-19
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Alberta, Chicoutimi, Halifax, Lethbridge, London, Montreal, Québec, Scarborough
2024-07-18
Active, closed
Vor Biopharma
Phase 3
191
London
2024-07-17
Recruiting
Colorado Prevention Center
Phase 3
1,500
Edmonton, Surrey, Greater Sudbury, London, North York, Toronto, Montreal, Sherbrooke
2024-07-09
Active, closed
AbbVie
Phase 3
1,400
Calgary, Edmonton, Kelowna, Fredericton, St. John's, Cobourg, Hamilton, London
2024-06-27
Recruiting
Canadian Cancer Trials Group
Phase 3
250
Vancouver, Winnipeg, St. John's, London, Ottawa, Montreal, Regina, Saskatoon
2024-06-26
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Vancouver, Halifax, London, Toronto, Montreal, Rimouski
2024-06-25
Recruiting
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
NCT06124976Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter
Peter Black
Phase 2/3
70
Vancouver, Winnipeg, Halifax, London, Toronto, Montreal, Sherbrooke
2024-06-19
Recruiting
Alimentiv Inc.
Observational
50
Hamilton, London
2024-06-19
Active, closed
Helius Medical Inc
Not applicable
60
Calgary, London, Verdun
2024-06-12
Active, closed
Takeda
Phase 4
60
Barrie, London, Mississauga, North Bay, North York, Oakville, Oshawa, Vaughan
2024-06-12
By invitation
Biomarkers in a Candian Memory Clinic
NCT06843109Alzheimer&#39;s Disease (AD)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2024-06-05
Recruiting
QED Therapeutics, a BridgeBio company
Observational
150
London, Ottawa, Montreal
2024-06-05
Active, closed
Amgen
Phase 3
563
London, Québec
2024-06-05
Not yet open
Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
NCT06153394Hepatic Disease, Surgery-Complications, Hypercoagulability, Thrombosis
DrugsFragmin·Dalteparin
Western University, Canada
Phase 3
50
London
2024-06-01
Recruiting
Douglas Mental Health University Institute
Observational
250
London, Montreal, Québec
2024-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,800
Calgary, Vancouver, Winnipeg, London, Ottawa, Toronto, Vaughan
2024-05-24
Active, closed
Albumin Utilization in Adult Cardiac Surgical Patients: Retrospective
NCT06322537Cardiovascular Surgical Procedures, Albumin
University Health Network, Toronto
Observational
505
New Westminster, Vancouver, Halifax, Hamilton, Kingston, London, Ottawa, Toronto
2024-05-23
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Calgary, Edmonton, Red Deer, Vancouver, Moncton, St. John's, Hamilton, London
2024-05-20
Active, closed
Pfizer
Observational
360
Kelowna, New Westminster, Richmond, Vancouver, London, Ottawa, Montreal
2024-05-08
Active, closed
Sanofi
Phase 3
1,541
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Winnipeg, Ajax, London
2024-05-08
Recruiting
Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study
NCT06249269Atrial Fibrillation, Paroxysmal or Persistent
Ratika Parkash
Observational
198
Calgary, Halifax, London, Ottawa, Toronto, Montreal, Regina
2024-05-01
Recruiting
iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
NCT06371937Cardiovascular Diseases, Arrythmia, Cardiomyopathies, Heart Failure
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
200
London
2024-05-01
Recruiting
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
NCT05884723Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
Anton Skaro
Not applicable
124
London
2024-05-01
Active, closed
Eli Lilly and Company
Phase 3
10,000
Calgary, Chicoutimi, Courtice, Edmonton, London, Moncton, North York, Oshawa
2024-04-30
Recruiting
CSL Behring
Phase 2/3
3,110
Edmonton, Halifax, Hamilton, Kingston, London, Oshawa, Montreal, Longueuil
2024-04-27
Recruiting
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
NCT05591924Sepsis, ARDS, Critical Illness, Neurocognitive Dysfunction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
1,000
London
2024-04-26
Recruiting
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
NCT06335043Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
155
London
2024-04-25
Recruiting
Canadian Cancer Trials Group
Phase 3
710
St. John's, Barrie, Kingston, Kitchener, London, Mississauga, Oshawa, Toronto
2024-04-25
Recruiting
RAFT - Pace &Ablate
NCT06299514Atrial Fibrillation, Heart Failure, Pacemaker, Arrhythmia Atrial
Habib Khan
Not applicable
600
Victoria, Halifax, Hamilton, Kitchener, London, Newmarket, Ottawa, Toronto
2024-04-25
Recruiting
Prediction of Intraventricular Hemorrhage Using Echocardiography and Near Infrared Spectroscopy
NCT05708105Intraventricular Hemorrhage of Newborn Grade 2, Intraventricular Hemorrhage of Newborn Grade 3, Intraventricular Haemorrhage Grade IV
Mount Sinai Hospital, Canada
Observational
380
Calgary, Edmonton, London, Toronto
2024-04-22
Recruiting
David Palma
Observational
48
London
2024-04-19
Recruiting
National Cancer Institute (NCI)
Phase 3
478
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2024-04-19
Active, closed
Takeda
Phase 4
50
Edmonton, London, North Bay, North York, Oakville, Vaughan, Montreal
2024-04-18
Recruiting
Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)
NCT05452356Heart Diseases, Arrhythmias, Cardiac, Atrial Fibrillation, Cardiovascular Diseases
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
2,000
London
2024-04-18
Active, closed
Janssen-Cilag Ltd.
Phase 3
120
Calgary, London, Montreal
2024-04-17
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
90
London
2024-04-16
Recruiting
Tom Appleton
Phase 2
30
London
2024-04-15
Active, closed
Celldex Therapeutics
Phase 2
140
Edmonton, Barrie, Etobicoke, Guelph, London, Toronto
2024-04-12
Recruiting
AstraZeneca
Phase 3
3,850
New Westminster, North Vancouver, Vancouver, Winnipeg, Sydney, Cambridge, Hamilton, London
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Vancouver, Winnipeg, St. John's, London, Newmarket, Oshawa, Toronto, Lévis
2024-04-11
Recruiting
Western University, Canada
Observational
30
London, Toronto
2024-04-02
Active, closed
Takeda
Phase 2
213
Calgary, New Westminster, London, Montreal
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Winnipeg, Brampton, London, Toronto
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Edmonton, Vancouver, Winnipeg, Halifax, Sydney, Brampton, Concord, London
2024-03-29
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
DrugTovorafenib
National Cancer Institute (NCI)
Phase 2
48
Edmonton, Vancouver, Halifax, Hamilton, London, Toronto, Montreal, Sherbrooke
2024-03-28
Active, closed
Alimentiv Inc.
Observational
300
Edmonton, Vancouver, Brampton, London, Mississauga, Oakville, Ottawa, Scarborough Village
2024-03-20
Recruiting
Eli Lilly and Company
Phase 3
90
Halifax, London, Toronto, Vancouver
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Halifax, London, Toronto
2024-03-13
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Calgary, Vancouver, Winnipeg, London, Ottawa, Toronto, Vaughan
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Calgary, Halifax, London, Ottawa, Toronto, Montreal, Québec
2024-03-12
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Surrey, Winnipeg, London, Markham, Mississauga, Peterborough, Toronto, Windsor
2024-03-09
Active, closed
Eli Lilly and Company
Phase 3
17,300
Brampton, Chicoutimi, Hamilton, Joliette, London, Longueuil, Moncton, New Westminster
2024-03-05
Recruiting
Takeda
Phase 2
268
Calgary, New Westminster, Halifax, London, Toronto, Montreal
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Barrie, London, North York, Ottawa, Toronto, Montreal
2024-03-04
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
100
Winnipeg, Halifax, London
2024-03-01
Active, closed
Sanofi
Phase 3
464
Calgary, Edmonton, Burlington, Hamilton, London, Toronto, Québec, Regina
2024-02-29
Recruiting
Daiichi Sankyo
Phase 2/3
860
Calgary, London, Montreal, Ottawa, Toronto
2024-02-27
Active, closed
Dianthus Therapeutics
Phase 2
65
London
2024-02-23
Active, closed
Loneliness Group Intervention
NCT05619718Loneliness
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
50
London
2024-02-23
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Calgary, Vancouver, London
2024-02-22
Active, closed
AbbVie
Observational
1,200
Calgary, Edmonton, New Westminster, Winnipeg, Halifax, Barrie, London, Mississauga
2024-02-19
Recruiting
Italfarmaco
Phase 3
138
Vancouver, London, Ottawa, Toronto
2024-02-19
Recruiting
St. Justine's Hospital
Observational
3,000
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Kingston, London, Oshawa
2024-02-13
Active, closed
Genmab
Phase 3
1,095
London, Ottawa, Lévis, Montreal
2024-02-05
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
DrugsRelatlimab·Opdivo·Nivolumab
National Cancer Institute (NCI)
Phase 2/3
992
Calgary, Edmonton, Vancouver, Kitchener, London, Ottawa, Toronto, Regina
2024-02-02
Active, closed
Incyte Corporation
Phase 3
617
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Barrie, Hamilton, London
2024-01-30
Active, closed
PeRiopEratiVE SmokiNg CessaTion Trial
NCT05102123Smoking (Tobacco) Addiction, Smoking Cessation
DrugCytisine
Population Health Research Institute
Phase 3
1,720
Hamilton, Kingston, London
2024-01-15
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
DrugsLutetium Lu 177 Dotatate·Lutathera·Sunitinib·Cabozantinib
National Cancer Institute (NCI)
Phase 2
100
Vancouver, Winnipeg, St. John's, London, Ottawa, Toronto, Québec
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Calgary, Winnipeg, London, Toronto, Chicoutimi, Montreal, Rimouski
2024-01-11
Active, closed
Tenax Therapeutics, Inc.
Phase 3
230
Winnipeg, London
2024-01-10
By invitation
5-SENSE Score Validation Study
NCT06138808Epilepsy Intractable
Duke University
Observational
400
Dalhousie, London
2024-01-09
Recruiting
POHCA Resuscitation: Evaluation of IM Epinephrine
NCT05166343Pediatric Out-of-Hospital Cardiac Arrest
DrugEpinephrine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2/3
284
London
2024-01-08
Active, closed
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
DrugsHydrocortisone Sodium Succinate·Revumenib·Fludarabine Phosphate·Calaspargase Pegol
Children's Oncology Group
Phase 2
78
Vancouver, Winnipeg, Halifax, Hamilton, London, Ottawa, Toronto, Montreal
2024-01-08
Recruiting
Evaluation of the Transitional and Lifelong Care Program
NCT05849285Cerebral Palsy, Spina Bifida, Developmental Disability
Western University, Canada
Observational
410
London
2024-01-03
Recruiting
Emergency Medicine Pulmonary Embolism Testing Multicentre Study
NCT06320236Pulmonary Embolism, D-dimer, Diagnosis
Dr. Kerstin de Wit
Observational
4,000
Hamilton, Kingston, London, Ottawa
2024-01-01
Recruiting
A Nutrition and Exercise Lifestyle Intervention Program Participant Choice Approach
NCT06187675Lifestyle, Healthy, Pregnancy Related, Adherence, Treatment, Nutrition, Healthy
Western University, Canada
Not applicable
120
London
2024-01-01
Active, closed
Sanofi
Phase 3
943
Calgary, Burnaby, Vancouver, Moncton, London, Ottawa, Toronto, Gatineau
2023-12-27
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Calgary, Edmonton, Halifax, London
2023-12-20
Recruiting
Anxiolysis for Laceration Repair in Children
NCT05383495Laceration of Skin, Distress, Emotional
DrugsNitrous oxide·Midazolam·Dexmedetomidine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3
300
London
2023-12-19
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
367
Vancouver, Halifax, London, Toronto, Montreal
2023-12-14
Recruiting
AstraZeneca
Phase 3
1,145
Calgary, Edmonton, Kelowna, Kingston, London, Toronto, Chicoutimi, Montreal
2023-12-14
Active, closed
Sanofi
Phase 3
1,655
Edmonton, St. John's, London, Ottawa, Gatineau, Granby, Lévis, Québec
2023-12-13
Recruiting
AbbVie
Phase 3
110
Calgary, Edmonton, Vancouver, London
2023-12-11
Active, closed
Sanofi
Phase 2
197
Vancouver, London, Montreal
2023-12-11
Active, closed
Gilead Sciences
Phase 2
176
London, Toronto, Vaughan
2023-12-05
Active, closed
AnaptysBio, Inc.
Phase 2
132
London, Montreal, Calgary
2023-12-04
Active, closed
AstraZeneca
Phase 3
760
Vancouver, Halifax, Kingston, London, Ottawa, Toronto, Montreal, Québec
2023-12-04
Recruiting
Studying the Effects of Cannabis on Vasculature
NCT05581368Cardiovascular Diseases, Inflammation, Atherosclerosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2023-12-01
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Calgary, Vancouver, Winnipeg, Burlington, Cambridge, Hamilton, Kitchener, London
2023-11-30
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Children's Oncology Group
Observational
330
London
2023-11-30
Active, closed
Incyte Corporation
Phase 3
467
Calgary, Surrey, Burlington, London, North YORK, Ottawa, Peterborough, Waterloo
2023-11-29
Active, closed
argenx
Observational
413
London, Montreal, Québec, Saskatoon
2023-11-29
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
300
London
2023-11-20
Recruiting
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
NCT05417516Breast Neoplasm Female, Radiotherapy, Cosmetic Outcome
Ontario Clinical Oncology Group (OCOG)
Phase 3
910
Calgary, Victoria, Halifax, Barrie, Hamilton, London, Newmarket, Sault Ste. Marie
2023-11-20
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Calgary, London, Toronto, Montreal
2023-11-16
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Edmonton, Hamilton, London, Niagara Falls, Québec, Verdun
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Calgary, Vancouver, Barrie, London, Oshawa, Toronto, Lévis, Montreal
2023-11-14
Active, closed
Pfizer
Phase 3
1,571
Calgary, Edmonton, Vancouver, Winnipeg, Barrie, Greater Sudbury, London, Mississauga
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
London, Waterloo, Greenfield Park, Montreal
2023-11-07
Recruiting
University of Maryland, Baltimore
Phase 3
312
New Westminster, Vancouver, Hamilton, London, Ottawa
2023-11-05
Active, closed
Minimally Displaced Femoral Neck Fracture Pilot Study
NCT05947058Femoral Neck Fractures
University of Maryland, Baltimore
Not applicable
40
Vancouver, Hamilton, London
2023-11-01
Active, closed
Summit Therapeutics
Phase 3
1,600
London, Ottawa, Regina
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2023-10-25
Recruiting
University of Calgary
Phase 4
210
Calgary, Edmonton, Vancouver, Halifax, Brampton, Brantford, Hamilton, London
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
Calgary, Vancouver, London, Toronto
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
London, Ottawa, Toronto
2023-10-22
Recruiting
Investigating Genetic Status in Patients Presenting to Clinic
NCT05911932Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
1,000
London
2023-10-20
Active, closed
AskBio Inc
Phase 2
150
Winnipeg, St. John's, London, Toronto, Chicoutimi, Montreal, Québec
2023-10-20
Recruiting
NRG Oncology
Phase 3
3,960
Barrie, Kitchener, London, Oakville, Oshawa, Toronto, Montreal, Québec
2023-10-18
Recruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
138
London, Montreal
2023-10-16
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Calgary, Edmonton, Surrey, London, Newmarket, Toronto, Windsor, Montreal
2023-10-12
Active, closed
Virtual Physical Activity Seated Exercise - Phase 2
NCT05724823Stroke, Chronic Stroke, Stroke, Ischemic, Stroke Hemorrhagic
University of British Columbia
Not applicable
100
Vancouver, Winnipeg, Halifax, London, Saskatoon
2023-10-11
Recruiting
Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents
NCT05867472Intensive Care Units, Pediatric, Anesthetics, Inhalation, Mechanically Ventilated, Critically Ill Children
DrugIsoflurane Inhalant Product
Sunnybrook Health Sciences Centre
Phase 3
60
Hamilton, London, Toronto
2023-10-10
Recruiting
David Palma
Phase 3
180
Prince George, Vancouver, London, Montreal
2023-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Etobicoke, London, Toronto, Montreal
2023-10-02
Recruiting
Cannabidiol Medication Intervention Trial
NCT06014424Alzheimer Disease
Sunnybrook Health Sciences Centre
Phase 2
40
Calgary, London, Toronto, Whitby
2023-09-27
Recruiting
AstraZeneca
Phase 3
800
Hamilton, London, Toronto, Montreal, Ste-Foy
2023-09-22
Recruiting
Ottawa Hospital Research Institute
Not applicable
14,400
Calgary, Winnipeg, Greater Sudbury, Hawkesbury, London, North Bay, Thunder Bay, Toronto
2023-09-18
Active, closed
CTSN Embolic Protection Trial
NCT06027788Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease
Icahn School of Medicine at Mount Sinai
Not applicable
842
London, Ottawa, Montreal, Québec
2023-09-18
Active, closed
Canadian Cancer Trials Group
Phase 2
4
Winnipeg, Kingston, London, Ottawa, Toronto, Montreal, Québec
2023-09-15
Recruiting
Predictors of Risk in Left Ventricular Non-Compaction
NCT06024759Left Ventricular Noncompaction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
500
London
2023-09-01
Active, closed
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
DrugsCalaspargase Pegol·Oncaspar·PEG-Asparaginase·Pegaspargase
Children's Oncology Group
Phase 3
440
Halifax, London, Toronto
2023-08-24
Active, closed
Erasca, Inc.
Phase 1
86
Edmonton, Vancouver, London, Toronto
2023-08-17
Recruiting
Epineuron Technologies Inc.
Not applicable
110
Edmonton, Saint John, Hamilton, London, Newmarket, Toronto
2023-08-11
Active, closed
Hoffmann-La Roche
Phase 3
459
Vancouver, Sydney, London, Toronto, Montreal, Québec
2023-08-08
Rows per page Showing 1–500 of 878
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-canada/city/london

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,553 studies in total at the last sync on 10 Nov 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 878 of those studies with a site in London.

How many clinical trials are recruiting in London?

424 of the 878 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:20 UTC sync. A further 76 have not yet opened recruitment, 364 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 878 studies
PhaseStudiesRecruitingShare
Phase 332814037.4%
Not applicable20510023.3%
Phase 21296314.7%
Observational1267814.4%
Phase 426143%
Phase 2/324122.7%
Phase 11952.2%
Phase 1/21791.9%
Early Phase 1430.5%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's11054
Western University, Canada3718
AstraZeneca3617
Novartis Pharmaceuticals2614
Eli Lilly and Company2214
Canadian Cancer Trials Group199
AbbVie188
Hoffmann-La Roche176
National Cancer Institute (NCI)175
Janssen Research & Development, LLC157
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.